Alternative: if pre-money is $10M and existing shares are 10,000 at $3 → existing valuation = $30M → contradiction.

February 22, 2026

Alternative Explanation: Resolving the Contradiction Between Pre-Money Valuation and Existing Share Price

When evaluating startup financings, a common source of confusion arises when the pre-money valuation appears inconsistent with the existing share price — especially when pre-money is stated as $10 million and existing shares are priced at $3 each. At first glance, this may seem contradictory, but under certain Sarorie structures, dilution calculations, and share Autorized Capital analysis, this discrepancy can be resolved. This article explains the alternative reasoning behind such valuation scenarios and clarifies how pre-money valuations align with existing share prices in equity-heavy funding rounds.

The Apparent Contradiction

The core issue lies in calculating the pre-money valuation when existing shares and their per-share price are known:

Existing shares outstanding: 10,000 shares
Share price: $3 →
Existing pre-money valuation = 10,000 × $3 = $30M

However, pre-money valuation is stated as $10M — a $20M contradiction. How can $30M valuation coexist with $3 per share? The resolution hinges on understanding equity issuance terms, share authorizations, and capitalization structure, especially when outstanding shares do not fully reflect pre-money assumptions.

Understanding the Discrepancy: Share Authorization vs. Outstanding Shares

A common source of confusion is conflating authorized capital with existing outstanding shares. Supposedly, if an investor invests with a pre-money valuation of $10M, the implied price per existing share reflects that valuation — yet in this case, the share price is $3, pushing the pre-money estimate higher. The resolution lies in how shares were issued:

1. Existing Share Base May Not Fully Reflect Pre-Money Assumptions

If the $10M pre-money reflects entire equity value pre-investment, but only 10,000 shares are officially outstanding post-issue, the share price calculation depends on whether existing investors had rights relative to the cap table.

For instance:

Pre-money valuation: $10M
Existing shares outstanding: 10,000 shares at $3 → $30M implied pre-money
Contradiction? Not necessarily — if the $10M pre-money represents investor value after accounting for founder dilution, anti-dilution rights, or pro-rata participations.

2. Investor Preference, Effectiveness Price, and Unlisted Shares

Alternative explanations involve:

Investor holding preferred shares with liquidation preferences
Discounted or pro-rata pricing in secondary or pre-money rounds that don’t cleanly divide shares
Existing shares issued at different effective prices due to founding rounds, employee stock options, or prior convertible notes

In practice, discrepancies often emerge from:

Pre-money valuations based on expected future value, not immediately reflected share price
The cap table being partially diluted or adjusted outside of immediate pre-money math
Misalignment between book value and market-consensus cap table inputs

Alternative Resolution: Valuation Drivers Beyond Immediate Share Price

Rather than viewing $10M pre-money and $3/share as conflicting, consider:

A. Higher Future Potential Justifies Current Valuation

Investors often assign a $10M pre-money valuation based on the company’s projected growth, technology, product traction, or market capture — leading to a $3/share price that only materializes post-investment expansion. In this case, the existing $30M implied valuation assumes future liquidity events not yet priced in.

B. Market Rate vs. Internal Valuation

Startups may set pre-money valuations using investor benchmarks, comparable companies, or projected revenue — independent of current share issuance mechanics. The $10M pre-money could reflect:

The investor's expected return, not the exact share price conversion
Valuation multiples from similar pre-money rounds in the same sector

Thus, $3 per share may not represent the full pre-money weighted by dilution but rather a negotiated entry point considering growth pathways.

C. Share Rights and Anti-Dilution Adjustments

If existing shareholders retained protective provisions (e.g., anti-dilution clauses), the effective pre-money share price may diverge from straightforward $existing shares × $price multiplication. The $10M pre-money may embed these risk adjustments into valuation, not just outstanding share count.

Practical Implications for Investors and Founders

Recognizing the nuance helps avoid misinterpretations in fundraising:

Pre-money valuation is forward-looking, often detached from current share price mechanics
Existing share price reflects issued units at that round, which may not equal $10M pre-money without complex pro-rata or cap table modeling
Always reconcile cap table structure, investor preference structure, and dilution effects for accurate valuation alignment

Conclusion

The $10M pre-money and $3/share contradiction is not a mathematical error but a symptom of differing valuation philosophies and cap table realities. Modern venture funding often decouples share price per share from holistic pre-money valuation, incorporating growth expectations, investor risk premiums, and structured rights. By clarifying share authorizations, dilution history, and future value assumptions, investors and founders can resolve apparent inconsistencies and move past misleading surface-level figures toward equitable, transparent valuations.

Key Takeaways:

Pre-money valuation reflects investor-implied company value, not always immediate share price
Existing share price and valuation mismatches often stem from dilution, cap table complexity, or growth assumptions
Always analyze capital structure holistically — including share authorizations, investor terms, and future milestones — to interpret realistic pre-money figures

Understanding alternative explanations behind valuation discrepancies empowers smarter financing decisions in startup ecosystems.

Keyword focus: pre-money valuation, existing shares, cap table, stock price reconciliation, startup financing, alternative valuation reasoning, equity dilution, venture capital valuation, founder share pricing.